

## VI. Financial follow-up of housing programs

**27.** The director in charge of the financial follow-up of housing programs is authorized, within the scope of the director's responsibilities, to approve

(1) audited financial statements of bodies that manage 1,000 dwellings or less;

(2) the use by any body having carried out a housing project within a social and community housing program of their reserves, for any amount equal to or greater than \$50,000;

(3) budgetary amendments relating to the payment of the consideration to be paid by housing bureaus and other non-profit organizations determined by by-law pursuant to the Act.

**28.** Service heads under the authority of that director, as well as the professional assisting the director, are authorized, within the scope of their responsibilities, to approve

(1) audited financial statements of bodies that manage 300 dwellings or less; and

(2) terms of payment and use of financial assistance of less than \$25,000, as well as all confirmations, authorizations and other documents required to give full effect to the programs.

**29.** Financial analysts under the authority of that director are authorized, within the scope of their responsibilities, to approve the audited financial statements of bodies that manage 100 dwellings or less.

### DIVISION III MISCELLANEOUS AND FINAL

**30.** The signatures of the president and chief executive officer and of the vice-president may be affixed by means of an automatic device. A facsimile of such a signature may be engraved, lithographed or printed on cheques, drafts, notes, bills of exchange, bonds or other negotiable instruments.

**31.** This By-law replaces the By-law respecting the delegation of powers and signing of certain documents of the Société d'habitation du Québec (chapter S-8, r. 6).

**32.** This By-law comes into force on 27 december 2017.

Gouvernement du Québec

### O.C. 1249-2017, 13 December 2017

An Act respecting the Ministère de la Santé et des Services sociaux  
(chapter M-19.2)

Program for free universal access to voluntary medical termination of pregnancy (abortion pill)

WHEREAS, under paragraph *h* of section 3 of the Act respecting the Ministère de la Santé et des Services sociaux (chapter M-19.2), the Minister is to promote the development and implementation of programs and services according to the needs of individuals, and families and other groups;

WHEREAS, under the first paragraph of section 2 of the Act respecting the Régie de l'assurance maladie du Québec (chapter R-5), the function of the Board is to administer and implement the programs of the health insurance plan instituted by the Health Insurance Act (chapter A-29) and any other program entrusted to it by law or by the Government;

WHEREAS, under the fifteenth paragraph of section 3 of the Health Insurance Act, the Board assumes the cost of services and goods provided for under the programs it administers by virtue of the first paragraph of section 2 of the Act respecting the Régie de l'assurance maladie du Québec according to the conditions and methods provided for under those programs;

WHEREAS, under the first paragraph of section 2.1 of the Act respecting the Régie de l'assurance maladie du Québec, the Board recovers, from the department or body concerned, the cost of services and goods it assumes under a program entrusted to it by law or by the Government, to the extent provided for under that program;

IT IS ORDERED, therefore, on the recommendation of the Minister of Health and Social Services:

THAT the Program for free universal access to voluntary medical termination of pregnancy (abortion pill), attached to this Order in Council, be entrusted to the Régie de l'assurance maladie du Québec.

JUAN ROBERTO IGLESIAS,  
*Clerk of the Conseil exécutif*

PROGRAM FOR FREE UNIVERSAL ACCESS  
TO VOLUNTARY MEDICAL TERMINATION  
OF PREGNANCY (ABORTION PILL)

1. Every person must, to be eligible under the program, be a person insured within the meaning of subparagraph g.1 of the first paragraph of section 1 of the Health Insurance Act (chapter A-29), that is, a resident or temporary resident of Québec who is duly registered with the Régie de l'assurance maladie du Québec, and present to a pharmacist, a medical specialist or a general practitioner, as the case may be, his or her valid health insurance card, claim booklet or eligibility card, as the case may be.

2. The medications or other supply covered by this program are provided by a pharmacist on presentation of a prescription.

3. The type, cost, format and quantity of medications or supplies covered by this Program are those listed in Schedule A of this program, it being understood that the Minister of Health and Social Services may make an agreement at any time, by agreement with the Board, to add or remove medications or supplies from the list while complying with rules applicable in that respect. A medication or supply added to the list is deemed to be a medication or supply covered by this program, and indicated in Schedule A.

4. The Board only assumes the cost of medications and supplies indicated in Schedule A according to the type, format and quantity of medication or supply provided. The Board also only assumes the cost of the professional services provided for in the special agreement between the Minister and the Association québécoise des pharmaciens propriétaires related to the Program for free universal access to voluntary medical termination of pregnancy (abortion pill), the agreement between the Minister and the Fédération des médecins spécialistes du Québec and the agreement between the Minister and the Fédération des médecins omnipraticiens du Québec, at the tariff and on the conditions provided for therein.

5. The Minister reimburses the Board, according to the terms they agree to, the sums paid under this program.

6. A pharmacist, a medical specialist or a general practitioner covered by this program may exact or receive from the Board, for their services, only the remuneration provided for in the agreements referred to in section 4. The pharmacist, medical specialist or general practitioner may not require any payment whatsoever from an eligible person.

7. Persons who benefit from the program are exempt from the payment of any contribution.

8. A person eligible under the program who does not present his or her valid health insurance card, claim booklet or eligibility card must pay the cost of the professional services, which may not exceed the cost provided for in the agreements referred to in section 4. The person then applies to the Board for reimbursement using the form provided for that purpose.

9. Services and goods obtained outside Québec are not covered by this program except those provided by a pharmacist with whom the Board has entered into a special agreement for that purpose, where the pharmacy is situated in a region bordering Québec and, within a radius of 32 kilometers from the pharmacy, no Québec pharmacy serves the population.

10. The Board provides to the Minister periodic reports on expenses incurred under this program, according to the terms to which they may agree. The reports do not include personal information.

11. The Board publishes this program on its website within 30 days after the program takes effect. It also publishes the changes provided for in section 3 on its website, within 30 days after they take effect, so as to inform the population.

12. This program takes effect on 15 December 2017.

**SCHEDULE A**

<b>Type of medication</b>	<b>Content</b>	<b>Form</b>	<b>Format</b>	<b>Cost per format</b>
Mifepristone/ Misoprostol	200 mg/ 200 mcg	Kit	1	The purchase price of the medication by the pharmacist including a maximum wholesaler's profit margin of 6.5%, if applicable.
Dimenhydrinate	50 mg	Tablet	1	The purchase price of the medication by the pharmacist including a maximum wholesaler's profit margin of 6.5%, if applicable. The purchase price may not exceed the maximum refundable price of the medication, established by the Minister for the purposes of the program, to which is added the wholesaler's profit margin, if applicable. No excess may be claimed by the patient, even if the purchase price exceeds the maximum refundable price established for the purposes of the program.
Dimenhydrinate	15 mg/5 ml	Liquid	1 ml	The purchase price of the medication by the pharmacist including a maximum wholesaler's profit margin of 6.5%, if applicable. The purchase price may not exceed the maximum refundable price of the medication, established by the Minister for the purposes of the program, to which is added the wholesaler's profit margin, if applicable. No excess may be claimed by the patient, even if the purchase price exceeds the maximum refundable price established for the purposes of the program.
Dimenhydrinate	50 mg	Suppository	1	The purchase price of the medication by the pharmacist including a maximum wholesaler's profit margin of 6.5%, if applicable. The purchase price may not exceed the maximum refundable price of the medication, established by the Minister for the purposes of the program, to which is added the wholesaler's profit margin, if applicable. No excess may be claimed by the patient, even if the purchase price exceeds the maximum refundable price established for the purposes of the program.
Dimenhydrinate	100 mg	Suppository	1	The purchase price of the medication by the pharmacist including a maximum wholesaler's profit margin of 6.5%, if applicable. The purchase price may not exceed the maximum refundable price of the medication, established by the Minister for the purposes of the program, to which is added the wholesaler's profit margin, if applicable. No excess may be claimed by the patient, even if the purchase price exceeds the maximum refundable price established for the purposes of the program.